EQUILLIUM, INC. Payments of Stock Issuance Costs
EQUILLIUM, INC. (EQ) reported Payments of Stock Issuance Costs of $2.12 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2020-03-26
- EQUILLIUM, INC. payments of stock issuance costs for the quarter ending 2018-12-31 was $1.93M.
- EQUILLIUM, INC. payments of stock issuance costs for fiscal 2018 was $2.12M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 9 month as first filed | Payments of Stock Issuance Costs 12 month | Payments of Stock Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $2.12M 10-K · filed 2020-03-26 | $2.12M 10-K · filed 2019-03-27 | ||
| 2018-09-30 | $195.00K 10-Q · filed 2019-11-12 | $194.61K 10-Q · filed 2018-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |